| 32.71 2.85 (9.54%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 41.46 | 1-year : | 48.42 |
| Resists | First : | 35.5 | Second : | 41.46 |
| Pivot price | 31.98  |
|||
| Supports | First : | 21.56 | Second : | 12.94 |
| MAs | MA(5) : | 31.21 |
MA(20) : | 28.84 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 68  |
D(3) : | 71.1 |
| RSI | RSI(14): 75 |
|||
| 52-week | High : | 35.5 | Low : | 13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VOGX ] has closed below upper band by 37.2%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 33.04 - 33.18 | 33.18 - 33.3 |
| Low: | 29.27 - 29.4 | 29.4 - 29.53 |
| Close: | 32.47 - 32.71 | 32.71 - 32.93 |
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Thu, 03 Sep 2026
Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Vogenx, Inc. (VOGX) - theglobeandmail.com
Wed, 26 Aug 2026
Vogenx (NASDAQ: VOGX) CFO holds 700K shares plus options - Stock Titan
Wed, 26 Aug 2026
Vogenx (VOGX) insiders report 700,000-share stake in new filing - Stock Titan
Mon, 17 Aug 2026
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering - Yahoo Finance
Sun, 16 Aug 2026
Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs - medcitynews.com
Thu, 13 Aug 2026
Vogenx Inc. (VOGX) sentiment score, message volume, participation score and buzz level - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -297.37 |
| PEG Ratio | 0 |
| Price to Book value | -121.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -454.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|